Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes

This study has been completed.
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00954447
First received: August 6, 2009
Last updated: December 4, 2013
Last verified: October 2012
  Purpose

The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to Placebo during long term treatment (52 weeks and longer) in combination with basal insulin in patients with type 2 diabetes mellitus with insufficient glycaemic control.


Condition Intervention Phase
Diabetes Mellitus, Type 2
Drug: Placebo
Drug: Linagliptin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group Efficacy and Safety Study of Linagliptin (5 mg), Administered Orally Once Daily for at Least 52 Weeks in Type 2 Diabetic Patients in Combination With Basal Insulin Therapy

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Change From Baseline in HbA1c After 24 Weeks [ Time Frame: Baseline and 24 weeks ] [ Designated as safety issue: No ]
    HbA1c is measured as a percentage. Adjusted for treatment, baseline HbA1c, categorical renal function impairment and concomitant Oral antidiabetic drugs (OAD)


Secondary Outcome Measures:
  • Number of Patients With HbA1c < 7.0 Percent [ Time Frame: 24 and 52 weeks ] [ Designated as safety issue: No ]
  • Number of Patients Lowering HbA1c by at Least 0.5 Percent [ Time Frame: 24 and 52 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline in HbA1c by Visit at Week 6 [ Time Frame: Baseline and 6 weeks ] [ Designated as safety issue: No ]
    Means adjusted for treatment, baseline HbA1c, categorical renal function impairment and concomitant OADs

  • Change From Baseline in HbA1c by Visit at Week 12 [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
    Means adjusted for treatment, baseline HbA1c, categorical renal function impairment and concomitant OADs

  • Change From Baseline in HbA1c by Visit at Week 18 [ Time Frame: Baseline and 18 weeks ] [ Designated as safety issue: No ]
    Means adjusted for treatment, baseline HbA1c, categorical renal function impairment and concomitant OADs

  • Change From Baseline in HbA1c by Visit at Week 32 [ Time Frame: Baseline and 32 weeks ] [ Designated as safety issue: No ]
    Means adjusted for treatment, baseline HbA1c, categorical renal function impairment and concomitant OADs

  • Change From Baseline in HbA1c by Visit at Week 40 [ Time Frame: Baseline and 40 weeks ] [ Designated as safety issue: No ]
    Means adjusted for treatment, baseline HbA1c, categorical renal function impairment and concomitant OADs

  • Change From Baseline in HbA1c by Visit at Week 52 [ Time Frame: Baseline and 52 weeks ] [ Designated as safety issue: No ]
    Means adjusted for treatment, baseline HbA1c, categorical renal function impairment and concomitant OADs

  • Change From Baseline in Fasting Plasma Glucose (FPG) at 24 Weeks of Treatment [ Time Frame: Baseline and 24 weeks ] [ Designated as safety issue: No ]
    Means adjusted for treatment, baseline HbA1c, baseline FPG, categorical renal function impairment and concomitant OADs

  • Change From Baseline in Fasting Plasma Glucose (FPG) After 52 Weeks of Treatment [ Time Frame: Baseline and 52 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline in FPG [ Time Frame: Baseline, 6, 12, 18, 24, 32 and 40 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline in Mean Insulin Dose at 52 Weeks of Treatment [ Time Frame: Baseline and 52 weeks ] [ Designated as safety issue: No ]
    Means adjusted for treatment, continous baseline HbA1c, continous baseline weight, continous baseline Insulin, categorical renal function impairment and concomitant OADs

  • Change From Baseline in Weighted Mean Daily Glucose After 24 and 52 Weeks of Treatment [ Time Frame: Baseline, 24 and 52 weeks ] [ Designated as safety issue: No ]
    Mean Daily Glucose was calculated using the 8-point blood glucose profile

  • Change From Baseline in Incremental Post-prandial Glucose (iPPG) After 24 Weeks of Treatment [ Time Frame: Baseline and 24 weeks: post-breakfast, post-lunch, post-dinner ] [ Designated as safety issue: No ]

Other Outcome Measures:
  • Number of Patients With HbA1c < 6.5 Percent [ Time Frame: 24 and 52 weeks ] [ Designated as safety issue: No ]

Enrollment: 1263
Study Start Date: August 2009
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Linagliptin
patient receives a tablet with intended final marketed dose
Drug: Linagliptin
intended final marketed dose
Placebo Comparator: Placebo
patient receives a tablet identical to those containing Linagliptin
Drug: Placebo
Placebo, identical to Linagliptin tablet

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Diabetes type 2, detectable C-peptide, HbA1c 7-10%
  2. Pretreatment with basal insulin +/- Metformin or/and +/- Pioglitazone 3 Age > 18 years, BMI <= 45 kg/m2

Exclusion criteria:

  1. Uncontrolled hyperglycemia during Run-in
  2. Myocardial infarction, stroke or TIA within 3 months prior to informed consent
  3. Liver impairment; gastric surgery; medical history of cancer in last 5 years
  4. Other antidiabetic drugs, antiobesity drugs, systemic steroids, other investigational drug before randomisation
  5. Unsufficient birth control, pregnancy and nursing
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00954447

  Hide Study Locations
Locations
United States, California
1218.36.01051 Boehringer Ingelheim Investigational Site
Escondido, California, United States
1218.36.01043 Boehringer Ingelheim Investigational Site
Escondido, California, United States
1218.36.01065 Boehringer Ingelheim Investigational Site
Fresno, California, United States
1218.36.01021 Boehringer Ingelheim Investigational Site
Greenbrae, California, United States
1218.36.01013 Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
1218.36.01048 Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
1218.36.01058 Boehringer Ingelheim Investigational Site
San Diego, California, United States
1218.36.01008 Boehringer Ingelheim Investigational Site
Santa Ana, California, United States
United States, Connecticut
1218.36.01056 Boehringer Ingelheim Investigational Site
Waterbury, Connecticut, United States
United States, Florida
1218.36.01054 Boehringer Ingelheim Investigational Site
Clearwater, Florida, United States
1218.36.01035 Boehringer Ingelheim Investigational Site
Inverness, Florida, United States
1218.36.01010 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1218.36.01042 Boehringer Ingelheim Investigational Site
New Port Richey, Florida, United States
1218.36.01063 Boehringer Ingelheim Investigational Site
Pembroke Pines, Florida, United States
1218.36.01037 Boehringer Ingelheim Investigational Site
Ponte Vedra, Florida, United States
1218.36.01032 Boehringer Ingelheim Investigational Site
St. Cloud, Florida, United States
1218.36.01049 Boehringer Ingelheim Investigational Site
St. Petersburg, Florida, United States
United States, Georgia
1218.36.01036 Boehringer Ingelheim Investigational Site
Atlanta, Georgia, United States
1218.36.01047 Boehringer Ingelheim Investigational Site
Decatur, Georgia, United States
1218.36.01009 Boehringer Ingelheim Investigational Site
Roswell, Georgia, United States
United States, Hawaii
1218.36.01055 Boehringer Ingelheim Investigational Site
Honolulu, Hawaii, United States
United States, Illinois
1218.36.01014 Boehringer Ingelheim Investigational Site
Chicago, Illinois, United States
United States, Kentucky
1218.36.01011 Boehringer Ingelheim Investigational Site
Paducah, Kentucky, United States
United States, Missouri
1218.36.01040 Boehringer Ingelheim Investigational Site
Kansas City, Missouri, United States
1218.36.01029 Boehringer Ingelheim Investigational Site
St. Louis, Missouri, United States
1218.36.01034 Boehringer Ingelheim Investigational Site
St. Peters, Missouri, United States
United States, Nebraska
1218.36.01018 Boehringer Ingelheim Investigational Site
Omaha, Nebraska, United States
United States, New York
1218.36.01053 Boehringer Ingelheim Investigational Site
New Hartford, New York, United States
United States, North Carolina
1218.36.01006 Boehringer Ingelheim Investigational Site
Burlington, North Carolina, United States
1218.36.01025 Boehringer Ingelheim Investigational Site
Hickory, North Carolina, United States
1218.36.01005 Boehringer Ingelheim Investigational Site
Statesville, North Carolina, United States
United States, Ohio
1218.36.01015 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio, United States
United States, Oklahoma
1218.36.01039 Boehringer Ingelheim Investigational Site
Tulsa, Oklahoma, United States
United States, Pennsylvania
1218.36.01019 Boehringer Ingelheim Investigational Site
Altoona, Pennsylvania, United States
1218.36.01012 Boehringer Ingelheim Investigational Site
Norristown, Pennsylvania, United States
United States, South Carolina
1218.36.01004 Boehringer Ingelheim Investigational Site
Greer, South Carolina, United States
1218.36.01020 Boehringer Ingelheim Investigational Site
Simpsonville, South Carolina, United States
United States, Tennessee
1218.36.01003 Boehringer Ingelheim Investigational Site
Kingsport, Tennessee, United States
United States, Texas
1218.36.01038 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
1218.36.01016 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
United States, Utah
1218.36.01026 Boehringer Ingelheim Investigational Site
Salt Lake city, Utah, United States
United States, Vermont
1218.36.01041 Boehringer Ingelheim Investigational Site
Bennington, Vermont, United States
United States, Virginia
1218.36.01064 Boehringer Ingelheim Investigational Site
Richmond, Virginia, United States
United States, Washington
1218.36.01024 Boehringer Ingelheim Investigational Site
Lakewood, Washington, United States
1218.36.01007 Boehringer Ingelheim Investigational Site
Renton, Washington, United States
1218.36.01027 Boehringer Ingelheim Investigational Site
Spokane, Washington, United States
1218.36.01062 Boehringer Ingelheim Investigational Site
Tacoma, Washington, United States
Argentina
1218.36.54003 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1218.36.54002 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1218.36.54001 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1218.36.54005 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1218.36.54004 Boehringer Ingelheim Investigational Site
Córdoba, Argentina
Belgium
1218.36.320099 Boehringer Ingelheim Investigational Site
Edegem, Belgium
1218.36.32002 Boehringer Ingelheim Investigational Site
Edegem, Belgium
1218.36.32006 Boehringer Ingelheim Investigational Site
Sint-Gillis-Waas, Belgium
Brazil
1218.36.55003 Boehringer Ingelheim Investigational Site
Belém, Brazil
1218.36.55004 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
1218.36.55002 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
1218.36.55001 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
Canada, Alberta
1218.36.02010 Boehringer Ingelheim Investigational Site
Calgary, Alberta, Canada
Canada, British Columbia
1218.36.02004 Boehringer Ingelheim Investigational Site
Vancouver, British Columbia, Canada
1218.36.02011 Boehringer Ingelheim Investigational Site
Victoria, British Columbia, Canada
Canada, Newfoundland and Labrador
1218.36.02006 Boehringer Ingelheim Investigational Site
St. John's, Newfoundland and Labrador, Canada
Canada, Nova Scotia
1218.36.02002 Boehringer Ingelheim Investigational Site
Halifax, Nova Scotia, Canada
Canada, Ontario
1218.36.02009 Boehringer Ingelheim Investigational Site
Hamilton, Ontario, Canada
1218.36.02005 Boehringer Ingelheim Investigational Site
Kingston, Ontario, Canada
1218.36.02008 Boehringer Ingelheim Investigational Site
Sarnia, Ontario, Canada
1218.36.02007 Boehringer Ingelheim Investigational Site
Toronto, Ontario, Canada
Canada, Quebec
1218.36.02001 Boehringer Ingelheim Investigational Site
Laval, Quebec, Canada
1218.36.02003 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
Czech Republic
1218.36.42006 Boehringer Ingelheim Investigational Site
Breclav, Czech Republic
1218.36.42004 Boehringer Ingelheim Investigational Site
Brno, Czech Republic
1218.36.42005 Boehringer Ingelheim Investigational Site
Hodonin, Czech Republic
1218.36.42002 Boehringer Ingelheim Investigational Site
Mlada Boleslav, Czech Republic
1218.36.42001 Boehringer Ingelheim Investigational Site
Neratovice, Czech Republic
1218.36.42007 Boehringer Ingelheim Investigational Site
Zlin, Czech Republic
Finland
1218.36.35807 Boehringer Ingelheim Investigational Site
Joensuu, Finland
1218.36.35802 Boehringer Ingelheim Investigational Site
Kuopio, Finland
1218.36.35803 Boehringer Ingelheim Investigational Site
Oulu, Finland
1218.36.35805 Boehringer Ingelheim Investigational Site
Tampere, Finland
1218.36.35804 Boehringer Ingelheim Investigational Site
Turku, Finland
1218.36.35806 Boehringer Ingelheim Investigational Site
Vantaa, Finland
Germany
1218.36.49001 Boehringer Ingelheim Investigational Site
Berlin, Germany
1218.36.49002 Boehringer Ingelheim Investigational Site
Berlin, Germany
1218.36.49010 Boehringer Ingelheim Investigational Site
Berlin, Germany
1218.36.49009 Boehringer Ingelheim Investigational Site
Bosenheim, Germany
1218.36.49004 Boehringer Ingelheim Investigational Site
Dortmund, Germany
1218.36.49006 Boehringer Ingelheim Investigational Site
Dresden, Germany
1218.36.49017 Boehringer Ingelheim Investigational Site
Köln, Germany
1218.36.49012 Boehringer Ingelheim Investigational Site
Magdeburg, Germany
1218.36.49005 Boehringer Ingelheim Investigational Site
Mainz, Germany
1218.36.49018 Boehringer Ingelheim Investigational Site
Neuwied, Germany
1218.36.49008 Boehringer Ingelheim Investigational Site
Pirna, Germany
1218.36.49019 Boehringer Ingelheim Investigational Site
Sulzbach-Rosenberg, Germany
1218.36.49003 Boehringer Ingelheim Investigational Site
Unterschneidheim, Germany
1218.36.49011 Boehringer Ingelheim Investigational Site
Wangen, Germany
1218.36.49014 Boehringer Ingelheim Investigational Site
Wangen, Germany
1218.36.49015 Boehringer Ingelheim Investigational Site
Westerkappeln, Germany
Greece
1218.36.30010 Boehringer Ingelheim Investigational Site
Athens, Greece
1218.36.30003 Boehringer Ingelheim Investigational Site
Athens, Greece
1218.36.30007 Boehringer Ingelheim Investigational Site
Athens, Greece
1218.36.30011 Boehringer Ingelheim Investigational Site
Larissa, Greece
1218.36.30002 Boehringer Ingelheim Investigational Site
Nikaia, Greece
1218.36.30005 Boehringer Ingelheim Investigational Site
Thessaloniki, Greece
Italy
1218.36.39002 Boehringer Ingelheim Investigational Site
Ferrara, Italy
1218.36.39003 Boehringer Ingelheim Investigational Site
Ferrara, Italy
1218.36.39004 Boehringer Ingelheim Investigational Site
Genova, Italy
1218.36.39005 Boehringer Ingelheim Investigational Site
Milano, Italy
1218.36.39001 Boehringer Ingelheim Investigational Site
Pordenone, Italy
1218.36.39007 Boehringer Ingelheim Investigational Site
Siena, Italy
1218.36.39006 Boehringer Ingelheim Investigational Site
Siracusa, Italy
Korea, Republic of
1218.36.82004 Boehringer Ingelheim Investigational Site
Daegu, Korea, Republic of
1218.36.82009 Boehringer Ingelheim Investigational Site
Daegu, Korea, Republic of
1218.36.82008 Boehringer Ingelheim Investigational Site
Incheon, Korea, Republic of
1218.36.82007 Boehringer Ingelheim Investigational Site
Jeonju, Korea, Republic of
1218.36.82001 Boehringer Ingelheim Investigational Site
Pusan, Korea, Republic of
1218.36.82006 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1218.36.82005 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1218.36.82003 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1218.36.82002 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1218.36.82010 Boehringer Ingelheim Investigational Site
Suwon, Korea, Republic of
Mexico
1218.36.52002 Boehringer Ingelheim Investigational Site
Pachuca, Mexico
1218.36.52004 Boehringer Ingelheim Investigational Site
San Luis Potosi, Mexico
1218.36.52005 Boehringer Ingelheim Investigational Site
Tijuana, Mexico
Netherlands
1218.36.31008 Boehringer Ingelheim Investigational Site
's Hertogenbosch, Netherlands
1218.36.31001 Boehringer Ingelheim Investigational Site
Almere, Netherlands
1218.36.31006 Boehringer Ingelheim Investigational Site
Beek, Netherlands
1218.36.31002 Boehringer Ingelheim Investigational Site
Ewijk, Netherlands
1218.36.31004 Boehringer Ingelheim Investigational Site
Oude Pekela, Netherlands
1218.36.31007 Boehringer Ingelheim Investigational Site
Roelofarendsveen, Netherlands
1218.36.31005 Boehringer Ingelheim Investigational Site
Wildervank, Netherlands
Norway
1218.36.47002 Boehringer Ingelheim Investigational Site
Bergen, Norway
1218.36.47006 Boehringer Ingelheim Investigational Site
Elverum, Norway
1218.36.47005 Boehringer Ingelheim Investigational Site
Hamar, Norway
1218.36.47004 Boehringer Ingelheim Investigational Site
Oslo, Norway
1218.36.47001 Boehringer Ingelheim Investigational Site
Stavanger, Norway
Peru
1218.36.51003 Boehringer Ingelheim Investigational Site
Lima, Peru
Russian Federation
1218.36.70003 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1218.36.70002 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1218.36.70001 Boehringer Ingelheim Investigational Site
Samara, Russian Federation
1218.36.70007 Boehringer Ingelheim Investigational Site
Smolensk, Russian Federation
1218.36.70005 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
1218.36.70006 Boehringer Ingelheim Investigational Site
Yaroslavl, Russian Federation
Slovakia
1218.36.42103 Boehringer Ingelheim Investigational Site
Banska Bystrica, Slovakia
1218.36.42104 Boehringer Ingelheim Investigational Site
Bratislava, Slovakia
1218.36.42101 Boehringer Ingelheim Investigational Site
Bratislava, Slovakia
1218.36.42102 Boehringer Ingelheim Investigational Site
Bratislava, Slovakia
1218.36.42105 Boehringer Ingelheim Investigational Site
Presov, Slovakia
1218.36.42106 Boehringer Ingelheim Investigational Site
Trebisov, Slovakia
Spain
1218.36.34002 Boehringer Ingelheim Investigational Site
Badia del Vallés (Barcelona), Spain
1218.36.34010 Boehringer Ingelheim Investigational Site
Barcelona, Spain
1218.36.34005 Boehringer Ingelheim Investigational Site
Barcelona, Spain
1218.36.34001 Boehringer Ingelheim Investigational Site
Bercelona, Spain
1218.36.34007 Boehringer Ingelheim Investigational Site
Borges del Camp (Tarragona), Spain
1218.36.34003 Boehringer Ingelheim Investigational Site
Centelles (Barcelona), Spain
1218.36.34004 Boehringer Ingelheim Investigational Site
L'Hospitalet de Llobregat (Barcelona), Spain
1218.36.34011 Boehringer Ingelheim Investigational Site
Sevilla, Spain
1218.36.34009 Boehringer Ingelheim Investigational Site
Tàrrega (Lleida), Spain
1218.36.34006 Boehringer Ingelheim Investigational Site
Vic (Barcelona), Spain
Taiwan
1218.36.88610 Boehringer Ingelheim Investigational Site
Changhua, Taiwan
1218.36.88607 Boehringer Ingelheim Investigational Site
Kaohsiung, Taiwan
1218.36.88601 Boehringer Ingelheim Investigational Site
Taichung, Taiwan
1218.36.88603 Boehringer Ingelheim Investigational Site
Taichung, Taiwan
1218.36.88606 Boehringer Ingelheim Investigational Site
Tainan, Taiwan
1218.36.88605 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
1218.36.88604 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
1218.36.88602 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
1218.36.88608 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
1218.36.88609 Boehringer Ingelheim Investigational Site
Taipei City, Taiwan
Sponsors and Collaborators
Boehringer Ingelheim
Eli Lilly and Company
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Additional Information:
No publications provided by Boehringer Ingelheim

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT00954447     History of Changes
Other Study ID Numbers: 1218.36, 2008-008296-33
Study First Received: August 6, 2009
Results First Received: August 28, 2012
Last Updated: December 4, 2013
Health Authority: Argentina: Admin Nacional de Medicamentos, Alimentos Tecnologia Medica
Belgium: Federal Agency for Medicinal and Health Products
Brazil: National Health Surveillance Agency
Canada: Health Canada
Czech Republic: State Institute for Drug Control
Finland: Finnish Medicines Agency
Germany: Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), Kurt-Georg-Kiesinger-Allee 3, D-53175 Bonn
Greece: Ethics Committee
Italy: Ethics Committee
Korea: Food and Drug Administration
Mexico: Federal Commission for Protection Against Health Risks
Netherlands: Central Committee Research Involving Human Subjects
Norway: Norwegian Medicines Agency
Peru: Ministry of Health
Russia: Pharmacological Committee, Ministry of Health
Slovakia: State Institute for Drug Control
Spain: Ministry of Health
Taiwan: Department of Health
United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
BI 1356
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Hypoglycemic Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 24, 2014